Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non - small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Pyrimidines
  • Sulfonamides

abstract

  • Short-duration pazopanib was generally well tolerated and demonstrated single-agent activity in patients with early-stage NSCLC. Several target genes were dysregulated after pazopanib treatment, validating target-specific response and indicating a persistent pazopanib effect on lung cancer tissue. Further clinical evaluation of pazopanib in NSCLC is planned.

publication date

  • July 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.23.9749

PubMed ID

  • 20516450

Additional Document Info

start page

  • 3131

end page

  • 7

volume

  • 28

number

  • 19